

<b>Table S1. Retreatment options in DAA failure.</b>		
<b>Genotype</b>	<b>Regimen failure</b>	<b>Retreatment options</b>
GT1a	Daclatasvir/sofosbuvir Ledipasvir/sofosbuvir	Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Sofosbuvir/velpatasvir/voxilaprevir Sofosbuvir/grazoprevir/elbasvir/ribavirin
	Ritonavir-boosted paritaprevir, ombitasvir, and dasabuvir (3D)	Sofosbuvir/grazoprevir/elbasvir/ribavirin Sofosbuvir/velpatasvir/voxilaprevir Sofosbuvir plus glecaprevir/ pibrentasvir
GT1b	Daclatasvir/sofosbuvir Ledipasvir/sofosbuvir	PI with a second-generation NS5A inhibitor Sofosbuvir/velpatasvir/voxilaprevir
GT3	Daclatasvir/sofosbuvir	Glecaprevir/pibrentasvir Sofosbuvir/velpatasvir/voxilaprevir (With ribavirin in difficult-to-treat cases)
GT4	Daclatasvir/sofosbuvir Ledipasvir/sofosbuvir Ritonavir-boosted paritaprevir, ombitasvir (2D)	Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir